ipilimumab,nivolumab,cabozantinib
exelixis,bms
['nivo', 'cabozantinib', 'cosmic313', 'ipilimumab', 'nivolumab']
 the #cosmic313 phase iii trial has shown that adding cabozantinib to nivolumab-ipilimumab in first-line therapy can significantly reduce the risk of progression or death.
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre